# A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct03560271` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03560271](<https://clinicaltrials.gov/study/NCT03560271>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03560271

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

## Technical summary

Registry record NCT03560271. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-18 (actual); primary completion 2019-06-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 256 participants (enrolled count; ClinicalTrials.gov record NCT03560271, source copy `cardio:ctgov-nct03560271-2019-11-18`, retrieved 2026-10-26)
- Started: 2018-06-18 (actual) (ClinicalTrials.gov record NCT03560271, source copy `cardio:ctgov-nct03560271-2019-11-18`, retrieved 2026-10-26)
- Primary completion: 2019-06-25 (actual) (ClinicalTrials.gov record NCT03560271, source copy `cardio:ctgov-nct03560271-2019-11-18`, retrieved 2026-10-26)
- Completion: 2019-07-15 (actual) (ClinicalTrials.gov record NCT03560271, source copy `cardio:ctgov-nct03560271-2019-11-18`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03560271, source copy `cardio:ctgov-nct03560271-2019-11-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03560271-2019-11-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Cyclo-Z
- Intervention (Other): Placebo
- Lead sponsor: NovMetaPharma Co., Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: InClin, Inc.
- Collaborator class: INDUSTRY
- Collaborator: FGK Clinical Research GmbH
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 16693852b552e7425c916d0a73bad0f844c481e632e83f679ac65ce5684575f7
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
